Stem Cell Evidence
Stem Cell Evidence is an open access, comprehensive collection of high quality research relevant to haematopoietic stem cell transplantation. It provides a tailored search interface, with articles pre-selected for clinical relevance and methodological quality. This enables users to easily identify high quality papers relevant to their specific area of interest and to keep up-to-date in their field.
Stem Cell Evidence is updated regularly. Each month, the most important articles in the field are highlighted and the Stem Cell Evidence Alert is sent out to subscribers. The Stem Cell Evidence Alert is a digest of the top articles for current awareness in haematopoietic stem cell transplantation. Both the Stem Cell Evidence database and the Stem Cell Evidence Alert are available free of charge.
Stem Cell Evidence aims to be a key resource worldwide for medical practitioners, clinical researchers and policy makers. It is also intended to be of value to those planning new clinical trials in the field. It is produced by the Systematic Review Initiative and funded by the four UK Blood Services and Oxford Biomedical Research Centre.
Areas Covered
Articles which meet our eligibility criteria and clinical scope are entered into the database and search filters applied to them. This enables users to refine a search using filters, or browse the database to gain an overview in a subject area. Our search filters are structured in the following way:
- Transplant Type
- Condition - This is any medical condition which can be treated by haematopoietic stem cell transplantation, or a condition which arises from the transplant process
- Treatment - This is the process of transplantation from donor selection and care, through the transplant process and follow-up
- Patient Type
- Study Design
- Full Text Availability
- Date
Methodological scope
Articles must meet strict eligibility criteria to be selected for Stem Cell Evidence. The database is limited to systematic reviews, randomised controlled trials, overviews of systematic reviews, registry based studies, and observational studies that meet minimum patient number criteria.
Management
Stem Cell Evidence’s Clinical Management Group is headed by Dr James Griffin, who works closely with the SRI but is independent of the group.